Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Protocol: Ivosidenib + chemotherapy for IDH-mutated AML - Altai Oncology

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search

New Protocol: Ivosidenib + chemotherapy for IDH-mutated AML

New Protocol: Ivosidenib + chemotherapy for IDH-mutated AML
  • Phase I, multi-center, open-label study
  • Newly diagnosed acute myeloid leukemia with mutated IDH1 or IDH2
  • Continuous ivosidenib (mIDH1) or enasidenib (mIDH2) with induction 7 + 3 chemo
  • CR: 77% in mIDH1 & 74% in mIDH2
  • Treatment failure: 13% in mIDH1 & 13% in mIDH2
  • IDH mutation clearance: 39% in mIDH1 % 23% in mIDH2
  • OS @ 1 yr: 78% in mIDH1 & 76% in mIDH2
  • Grade >=3 non-heme AEs: QT prolongation (10% ivosidenib & 8% enasidenib), elevated bilirubin (7% ivosidenib & 16% enasidenib), rash (5% & 14%)

Blood. 2021;137(13):1792-1803

Stein EM, et al. Ivosidenib or enasidenib combined with intensivechemotherapy in patients with newly diagnosed AML:a phase 1 study


Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More